^
    Back
    Association details:
    Biomarker:HR negative
    Cancer:HER2 Positive Breast Cancer
    Drug:Perjeta (pertuzumab) (HER2 dimerization inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Farm Hosp
    Title:

    Real world study of pertuzumab-trastuzumabchemotherapy versus trastuzumab-chemotherapy in neoadjuvant treatment of breast cancer

    Published date:
    04/13/2020
    Excerpt:
    For patients with HER2 positive tumors and negative hormonal receptors with high risk criteria that receive pertuzumab, the complete pathological response is superior, with no increase in cardiac toxicity.
    DOI:
    10.7399/fh.11376